NE
NEPH.US Nephros Inc
- Market cap
- USD 33.2M
- P/E
- 17.9x
- P/B
- 2.64x
- ROE
- 19.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NEPH.US undervalued?
Graham numberNEPH.US trades 45.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nephros Inc fundamental analysis
No fundamental analysis for Nephros Inc yet.
Nephros Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nephros Inc
Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare …
Full company profileNephros Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nephros Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.32M | 3.81M | 5.69M | 10.3M | 8.56M | 10.2M | 9.98M | 14.2M | 14.2M | 18.8M | 22.5M |
| Gross Profit | 1.29M | 2.29M | 3.20M | 6.08M | 4.91M | 5.63M | 4.73M | 8.41M | 8.72M | 11.5M | 13.7M |
| Operating Income | -2.87M | -2.23M | -3.02M | -3.16M | -4.28M | -3.25M | -4.34M | -1.59M | 6.00K | 1.15M | 2.41M |
| EBITDA | -2.63M | -2.08M | -3.08M | -3.01M | -4.21M | -2.49M | -3.91M | -1.36M | 227K | 1.35M | 2.60M |
| Net Income | -3.03M | -809K | -3.40M | -3.42M | -4.77M | -4.11M | -7.38M | -1.58M | 74.0K | 1.19M | 2.47M |
| EPS | -0.56 | -0.14 | -0.50 | -0.45 | -0.52 | -0.41 | -0.72 | -0.15 | 0.01 | 0.11 | 0.22 |
| Balance Sheet | |||||||||||
| Total Assets | 2.68M | 4.98M | 10.6M | 11.6M | 18.5M | 17.7M | 11.0M | 11.9M | 11.2M | 13.6M | 15.3M |
| Total Liabilities | 2.01M | 3.03M | 3.76M | 3.94M | 2.94M | 2.90M | 2.12M | 3.50M | 2.63M | 3.44M | 2.76M |
| Shareholders' Equity | 667K | 1.95M | 3.80M | 4.68M | 12.5M | 11.7M | 5.59M | 8.36M | 8.59M | 10.2M | 12.5M |
| Cash & Short-term Investments | 302K | 2.21M | 4.58M | 4.17M | 8.25M | 6.97M | 3.63M | 4.31M | 3.76M | 5.40M | 4.55M |
| Total Debt | 838K | 1.67M | 2.03M | 2.55M | 2.17M | 1.00M | 1.09M | 1.84M | 1.41M | 1.06M | 774K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.11M | -77.0K | -3.66M | -2.28M | -6.90M | -1.42M | -3.23M | 827K | -492K | 1.65M | -1.52M |
| Capital Expenditure | 45.0K | 14.0K | 14.0K | 14.0K | 239K | 36.0K | 137K | 75.0K | 55.0K | 0.00 | 0.00 |
| Free Cash Flow | -2.16M | -77.0K | -3.66M | -2.29M | -7.14M | -1.45M | -3.37M | 752K | -547K | 1.65M | -1.52M |
| Ratios | |||||||||||
| ROE | -454.6% | -41.5% | -89.6% | -73.2% | -38.1% | -35.1% | -132.0% | -18.8% | 0.9% | 11.7% | 19.6% |
| ROA | -113.2% | -16.2% | -32.2% | -29.4% | -25.7% | -23.3% | -67.1% | -13.3% | 0.7% | 8.8% | 16.1% |
| Net Profit Margin | -130.7% | -21.2% | -59.8% | -33.1% | -55.7% | -40.2% | -74.0% | -11.1% | 0.5% | 6.4% | 11.0% |
| Debt to Equity | 1.26x | 0.85x | 0.53x | 0.54x | 0.17x | 0.09x | 0.20x | 0.22x | 0.16x | 0.10x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nephros Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 276K | 0.03 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:9 on Jul 10, 2019.
Who owns Nephros Inc
- Insiders 19.52%
- Institutions 20.87%
- Public & others 59.61%
- Shares outstanding 10.9M
- Free float 8.93M
Top funds holding NEPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 131K | 1.20% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 32.0K | 0.29% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 19.5K | 0.18% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 11.6K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 9.53K | 0.09% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 4.81K | 0.04% | 0.00% | Oct 2026 |
| DFA U.S. Core Equity 1 I | 4.80K | 0.04% | +105.53% | Sep 2026 |
| DFA US Sustainability Core 1 | 3.34K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 3.09K | 0.03% | 0.00% | Aug 2026 |
| DFA U.S. Core Equity 2 Instl | 2.73K | 0.03% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 1 ETF | 2.46K | 0.02% | 0.00% | Sep 2026 |
| DFA US Social Core Equity 2 Portfolio | 2.33K | 0.02% | 0.00% | Sep 2026 |
| DFA U.S. Vector Equity I | 1.42K | 0.01% | 0.00% | Sep 2026 |
| DFA US Core Equity Class F | 1.28K | 0.01% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 1.08K | 0.01% | 0.00% | Sep 2026 |
| Dimensional US Core Equity USD Acc | 1.05K | 0.01% | 0.00% | Sep 2026 |
| Dimensional US Sustainability Core 1 ETF | 409.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding NEPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Wexford Capital LP | 3.60M | 33.12% | 0.00% | Jun 2026 |
| Topline Capital Management LLC | 536K | 4.93% | -7.95% | Jun 2026 |
| Vanguard Capital Management, LLC | 199K | 1.83% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 129K | 1.19% | +16.23% | Jun 2026 |
| Petersen Flynn & Dinsmore Inc | 129K | 1.18% | 0.00% | Jun 2026 |
| Bard Associates Inc | 118K | 1.09% | -2.64% | Jun 2026 |
| Renaissance Technologies Corp | 71.1K | 0.65% | -8.26% | Sep 2026 |
| Geode Capital Management, LLC | 70.3K | 0.65% | -3.65% | Jun 2026 |
| Mesirow Fin Investmt Mgmt Intl Equity | 60.0K | 0.55% | -50.00% | Jun 2026 |
| HighTower Advisors, LLC | 59.7K | 0.55% | 0.00% | Jun 2026 |
| Navellier & Associates Inc | 53.5K | 0.49% | +179.61% | Jun 2026 |
| Essex Investment Management Company, LLC | 38.9K | 0.36% | -0.15% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 36.9K | 0.34% | 0.00% | Jun 2026 |
| Blair William & Co | 36.2K | 0.33% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 29.0K | 0.27% | +39.05% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 22.2K | 0.20% | 0.00% | Sep 2026 |
| BlackRock Inc | 18.8K | 0.17% | 0.00% | Jun 2026 |
| Northern Trust Corp | 16.7K | 0.15% | +54.29% | Jun 2026 |
| State Street Corp | 15.7K | 0.14% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 12.8K | 0.12% | -9.37% | Jun 2026 |
Nephros Inc company profile
- Company name
- Nephros Inc
- Ticker
- NEPH.US
- Exchange
- USA Stocks
- Listed since
- Sep 21, 2004
- Sector
- Healthcare
- Industry
- Household Durables
- Employees
- 36
- Fiscal year end
- December
- Address
- 380 Lackawanna Place, South Orange, NJ, United States, 07079
- Phone
- 201 343 5202
- Website
- nephros.com
About Nephros Inc
Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water; reduce biofilm and scale build-up; and remove cysts, particulates, and lead from water systems. It markets its products to food service and hospitality sectors including quick-service restaurants, convenience stores, and restaurants. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Nephros Inc management
7- Mr. Robert BanksPresident, CEO & Director · born 1975
- Ms. Judy F. Krandel C.F.A.Chief Financial Officer · born 1965
- Brianne McGuireDirector of Brand, Marketing & Business Development
- Vashone R. ThomasVice President of Quality, Regulatory, & Human Resources
- Mr. Greg LucasPresident of Aether Water Systems
- Ms. Judy MazziniController
- Mr. Michael MilmanVice President of R&D